PUB015 the Use of Immunohistochemistry Improves the Diagnosis of SCLC. an International Reproducibility Study in a Demanding Set of Cases
Erik Thunnissen,Alain Borczuk,Douglas Flieder,Birgit Witte,Mary Beasley,Jin-Haeng Chung,Sanja Dacic,Sylvie Lantuejoul,Prudence Russell,Michael Den Bakker,Johan Botling,Elisabeth Brambilla,Erienne De Cuba,Kim Geisinger,Kenzo Hiroshima,Alberto Marchevsky,Yuko Minami,Andre Moreira,Andrew Nicholson,Akihiko Yoshida,Ming Tsao,Arne Warth,Edwina Duhig,Gang Chen,Yoshihiro Matsuno,William Travis,Kelly Butnor,Wendy Cooper,Mari Mino-Kenudson,Noriko Motoi,Claudia Polari,Giuseppe Pelosi,Keith Kerr,Yuichi Ishikawa,Reinhard Buettner,Naoto Keino,Yasushi Yatabe,Masayuki Noguchi
DOI: https://doi.org/10.1016/j.jtho.2016.11.1985
IF: 20.121
2017-01-01
Journal of Thoracic Oncology
Abstract:The current World Health Organization (WHO) classification of lung cancer states that a diagnosis of small cell lung carcinoma (SCLC) can be reliably made on routine histological and cytological grounds, but immunohistochemistry may be required for confirmation of neuroendocrine and epithelial nature of the tumor cells. In addition, in small biopsies, the proliferation activity of SCLC as assessed by Ki-67 antigen immunostaining should be performed to avoid misdiagnosing carcinoid tumors in the presence of crush artifact. However, reproducibility studies on H&E alone for SCLC versus large cell neuroendocrine carcinoma have shown pairwise kappa scores ranging from 0.35 – 0.81. In the diagnostic process of SCLC, IHC may be useful i) in cases where histologic features are equivocal and ii) in cases where the pathologist wants to gain confidence. This study examines whether judicious use of immunohistochemistry (IHC) improves diagnostic reproducibility for SCLC. Nineteen lung pathologists studied interactive digital images of 79 tumors predominantly neuroendocrine lung tumors. Resection and biopsy sample images were diagnosed solely on morphology (level 1), morphology along with requested immunohistochemical stains (level 2), and with all available immunohistochemical stains (level 3). For the 19 pathologists reading all 79 cases the agreement rate for level 1 was 64.7% and increased to 73.2% and 77.5% in levels 2 and 3, respectively. With IHC, kappa scores for four tumor categories (SCLC, LCNEC, carcinoid tumors, and other) increased in resection samples from 0.43 to 0.60 and in biopsy samples from 0.43 to 0.64. An approach for IHC in the differential diagnosis of SCLC is provided and needs further confirmation, preferably linked to treatment outcome. In this set of challenging cases H&E stand alone diagnosis on “neuroendocrine appearing” tumors performs well, but is improved in most cases by the judicious use of IHC in the diagnosis of SCLC, where histologic features are equivocal or when the pathologist wants to gain confidence.